Showing 1941-1950 of 2150 results for "".
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur
- FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/fda-accepts-genentechs-biologics-license-application-for-satralizumab-for-neuromyelitis-optica-spectrum-disorder/2477055/Genentech announced the FDA has accepted the company’s biologics license application (BLA) for satralizumab for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD). The European Medicines Agency (EMA) has also validated the company’s Marketing Authorization
- IDx Taps Former LabCorp Executive to Lead Sales and Customer Successhttps://modernod.com/news/idx-taps-former-labcorp-executive-to-lead-sales-and-customer-success/2477030/IDx Technologies announced that it has appointed former LabCorp executive Seth Rainford as President of Global Markets. In his newly created role, Mr. Rainford will be charged with expanding market opportunities and driving operational excellence at IDx. “Se
- Intelligent Retinal Imaging Systems (IRIS) Partners with Remidio Innovative Solutions to Provide Early Detection Systems for Diabetic Eye Diseasehttps://modernod.com/news/intelligent-retinal-imaging-systems-iris-partners-with-remidio-innovative-solutions-to-provide-early-detection-systems-for-diabetic-eye-disease/2476989/Intelligent Retinal Imaging Systems (IRIS) announced a partnership with Remidio Innovative Solutions to bring their smartphone based non-mydriatic fundus camera to the U.S. market. Coupling the IRIS software and services program with an affordable and high-quality handheld camera will allow more
- Product Specific J-Code for Omeros’ Omidria is Now in Effecthttps://modernod.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/Omeros announced that the product specific J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is now effective. Omidria is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code f
- Ocugen Announces Completion of its Merger with Histogenics to Create Ocular Gene Therapies and Biotherapeuticshttps://modernod.com/news/ocugen-announces-completion-of-its-merger-with-histogenics-to-create-ocular-gene-therapies-and-biotherapeutics/2476924/Ocugen announced the completion of its merger with Histogenics, and the change of the combined company’s name to “Ocugen, Inc.” Ocugen is expected to begin trading today on The Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team of Ocugen has become the executive team of the
- Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa in the European Unionhttps://modernod.com/news/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-rhokiinsa-in-the-european-union/2476906/Aerie Pharmaceuticals announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorization application (MAA) for Rhokiinsa (netarsudilophthalmic solution) 0.02%. The recommend
- Sifi Appoints New Country Manager for Italyhttps://modernod.com/news/sifi-appoints-new-country-manager-for-italy/2476904/Sifi has announced that Fabrizio Folco has joined the company as “Country Manager Italy,” and will be responsible for accelerating company development on the Italian market through management of the company’s commercial strategy and organization, for both pharma and surgical are
- Allergan and Molecular Partners Announce Acceptance of FDA BLA for Abicipar Pegol in Patients With Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-acceptance-of-fda-biologics-license-application-for-abicipar-pegol-in-patients-with-wet-amd/2479537/Allergan and Molecular Partners announced that the FDA has accepted a biologics license application (BLA) and the European Medicines Agency (EMA) has validated a marketing authorization application (MAA) for Abicipar pegol, a novel, investigational DARPin therapy in patients with wet age-related